Kesatuan Eropah - Portugis - EMA (European Medicines Agency)

astrazeneca ab - osimertinib mesilate - carcinoma, pulmão de células não pequenas - outros agentes antineoplásicos, inibidores de proteína quinase - tagrisso as monotherapy is indicated for:- the adjuvant treatment after complete tumour resection in adult patients with stage ib-iiia non-small cell lung cancer (nsclc) whose tumours have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 (l858r) substitution mutations- the first-line treatment of adult patients nsclc with activating egfr mutations. - the treatment of adult patients with locally advanced or metastatic egfr t790m mutation-positive nsclc. tagrisso as monotherapy is indicated for:- the adjuvant treatment after complete tumour resection in adult patients with stage ib-iiia non-small cell lung cancer (nsclc) whose tumours have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 (l858r) substitution mutations. - the first-line treatment of adult patients with locally advanced or metastatic nsclc with activating egfr mutations. - the treatment of adult patients with locally advanced or metastatic egfr t790m mutation-positive nsclc.

Kesatuan Eropah - Portugis - EMA (European Medicines Agency)

astrazeneca ab - saxagliptin - diabetes mellitus, tipo 2 - drogas usadas em diabetes - add-on combination therapyonglyza is indicated in adult patients aged 18 years and older with type-2 diabetes mellitus to improve glycaemic control:as monotherapy:in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance;as dual oral therapy:in combination with metformin, when metformin alone, with diet and exercise, does not provide adequate glycaemic control;in combination with a sulphonylurea, when the sulphonylurea alone, with diet and exercise, does not provide adequate glycaemic control in patients for whom use of metformin is considered inappropriate;in combination with a thiazolidinedione, when the thiazolidinedione alone with diet and exercise, does not provide adequate glycaemic control in patients for whom use of a thiazolidinedione is considered appropriate;as triple oral therapy:in combination with metformin plus a sulphonylurea when this regimen alone, with diet and exercise, does not provide adequate glycaemic control;as combination therapy with insulin (with or without metformin), when this regimen alone, with diet and exercise, does not provide adequate glycaemic control.

Kesatuan Eropah - Portugis - EMA (European Medicines Agency)

astrazeneca ab - benralizumab - asma - medicamentos para obstrutiva, doenças das vias respiratórias, - fasenra é indicada como um complemento no tratamento de manutenção em pacientes adultos com graves eosinofílica asma inadequadamente controlada, apesar de altas doses de corticosteróides inalados mais longa ação de agonistas β.

Kesatuan Eropah - Portugis - EMA (European Medicines Agency)

astrazeneca ab - de sódio de zircónio cyclosilicate - hipercalemia - todos os outros produtos terapêuticos - lokelma é indicado para o tratamento de hyperkalaemia em pacientes adultos.

Kesatuan Eropah - Portugis - EMA (European Medicines Agency)

astrazeneca ab - durvalumab - carcinoma, pulmão de células não pequenas - agentes antineoplásicos - non-small cell lung cancer (nsclc)imfinzi as monotherapy is indicated for the treatment of locally advanced, unresectable non small cell lung cancer (nsclc) in adults whose tumours express pd-l1 on ≥ 1% of tumour cells and whose disease has not progressed following platinum based chemoradiation therapy (see section 5. imfinzi in combination with tremelimumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic nsclc with no sensitising egfr mutations or alk positive mutations. small cell lung cancer (sclc)imfinzi in combination with etoposide and either carboplatin or cisplatin is indicated for the first-line treatment of adults with extensive-stage small cell lung cancer (es-sclc). biliary tract cancer (btc)imfinzi in combination with gemcitabine and cisplatin is indicated for the first line treatment of adults with unresectable or metastatic biliary tract cancer (btc). hepatocellular carcinoma (hcc)imfinzi in combination with tremelimumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc).

Kesatuan Eropah - Portugis - EMA (European Medicines Agency)

astrazeneca ab - glycopyrronium, formoterol fumarate dihydrate - doença pulmonar, obstrução crônica - formoterol e glycopyrronium brometo de - bevespi aerosphere é indicado como broncodilatador de manutenção de tratamento para aliviar os sintomas, em doentes adultos com doença pulmonar obstrutiva crônica (dpoc).

Brazil - Portugis - ANVISA (Agência Nacional de Vigilância Sanitária)

astrazeneca do brasil ltda - candesartana cilexetila - anti-hipertensivos simples

Brazil - Portugis - ANVISA (Agência Nacional de Vigilância Sanitária)

astrazeneca do brasil ltda - candesartana cilexetila, felodipino - anti-hipertensivos simples

Brazil - Portugis - ANVISA (Agência Nacional de Vigilância Sanitária)

astrazeneca do brasil ltda - fulvestranto - antineoplasico

Brazil - Portugis - ANVISA (Agência Nacional de Vigilância Sanitária)

astrazeneca do brasil ltda - saxagliptina - antidiabeticos